Item 7.01. Regulation FD Disclosure.
As previously announced, the following medicines and/or new indications of
•Tislelizumab is included in the NRDL in all five of its approved indications -
three new indications included since
•For use in combination with pemetrexed and platinum chemotherapy as a
first-line treatment in patients with unresectable, locally advanced or
metastatic non-squamous non-small cell lung cancer (NSCLC), with EGFR genomic
tumor aberrations negative and ALK genomic tumor negative (approved in
•For the treatment of patients with hepatocellular carcinoma (HCC) who have been
previously treated with at least one systemic therapy (conditionally approved in
•For use in combination with paclitaxel and carboplatin as a first-line
treatment in patients with unresectable, locally advanced or metastatic squamous
NSCLC (approved in
•For the treatment of patients with locally advanced or metastatic urothelial
carcinoma (UC) with PD-L1 high expression whose disease progressed during or
following platinum-containing chemotherapy or within 12 months of neoadjuvant or
adjuvant treatment with platinum-containing chemotherapy (conditionally approved
in
•For the treatment of patients with classical Hodgkin's lymphoma (cHL) who have
received at least two prior therapies (conditionally approved in
•BRUKINSA® is included in the NRDL in all three of its approved indications -
one new indication since
•For the treatment of adult patients with Waldenström's macroglobulinemia (WM)
who have received at least one prior therapy (conditionally approved in
•For the treatment of adult patients with mantle cell lymphoma (MCL) who have
received at least one prior therapy (conditionally approved in
•For the treatment of adult patients with chronic lymphocytic leukemia (CLL)
/small lymphocytic lymphoma (SLL) who have received at least one prior therapy
(conditionally approved in
•Pamiparib is included in the NRDL since
•For the treatment of patients with germline BRCA (gBRCA) mutation-associated
recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who
have been treated with two or more lines of chemotherapy (conditionally approved
in
Item 8.01. Other Events.
On
--------------------------------------------------------------------------------
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release titled "China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small CellLung Cancer ", issued byBeiGene, Ltd. onJanuary 6, 2022 . 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
--------------------------------------------------------------------------------
© Edgar Online, source